Tonix Pharmaceuticals Expands TONMYA Medicare Coverage to 145 Million Lives

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced a significant expansion of Medicare coverage for TONMYA (cyclobenzaprine HCl sublingual tablets), its recently approved treatment for fibromyalgia. The new managed Medicare agreement will add approximately 9 million Medicare beneficiaries effective January 1, 2027. Combined with previously announced commercial coverage agreements and broad Medicaid availability, TONMYA will have pharmacy coverage reaching approximately 145 million covered lives, or 46% of the U.S. covered market. The company continues discussions with additional commercial and Medicare payers to further expand access.

This coverage expansion follows positive launch metrics for TONMYA, which is the first new treatment for fibromyalgia in more than 15 years. To support the growing demand, Tonix plans to add 50 sales representatives by mid-third quarter 2026, increasing its commercial sales force to approximately 150 people. The company is also expanding marketing and medical affairs initiatives to increase awareness of TONMYA as a first-in-class, non-opioid treatment option for fibromyalgia.

Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA is the company’s flagship medicine, and its CNS commercial infrastructure supports other marketed products, including acute migraine products Zembrace SymTouch and Tosymra. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Additionally, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

The expanded coverage underscores the importance of TONMYA as a non-opioid alternative for fibromyalgia, a condition affecting millions of Americans. With 145 million covered lives, Tonix is positioned to reach a substantial portion of the patient population. For more information, visit the company’s newsroom at https://ibn.fm/TNXP.